Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 10/20 | 0.48 |
| ▸ | JUN | P05412 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558951 | 1.00 | MAPK10 (0.48) | MAPK10JUNMAPK8TDP1GSK3A | |
| SCHEMBL558950 | 1.00 | MAPK10 (0.48) | MAPK10JUNMAPK8TDP1GSK3A | |
| SCHEMBL10166313 | 0.82 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9 | |
| SCHEMBL558845 | 0.82 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9 | |
| SCHEMBL558844 | 0.82 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9 | |
| SCHEMBL559150 | 0.81 | JUN (0.52) | MAPK10JUNMAPK8 | |
| SCHEMBL559151 | 0.81 | JUN (0.52) | MAPK10JUNMAPK8 | |
| SCHEMBL559816 | 0.80 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL10166315 | 0.80 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL559817 | 0.80 | MAPK10 (0.52) | MAPK10JUNMAPK8MAPK9TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK10 32/4885JUN 36/4885MAPK8 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.